

Q-Med's election committee presents its proposal for a new Board

As has been announced previously, Lyftet Holding BV has requested an Extraordinary General Meeting of the shareholders to elect a new Board for Q-Med AB. In this connection the election committee presents the following proposal, for resolution at the Extraordinary General Meeting on February 4. The election committee's proposal has the support of owners representing just under 70 percent of the total number of shares in the company.

The election committee consists of:

Robert Wikholm, Chairman
Anders Milton
Jan-Erik Erenius, AMF Pension

It is proposed that **Bertil Hult**, a member of the Board of Q-Med since 2006, be re-elected. He is the CEO of the Skandia Insurance Company (publ) and CEO of Skandia's Nordic Division. Bertil Hult is, amongst other things, Chairman of Asia Growth Investors AB and eTurn Capital Management AB, and has a number of Board assignments in Skandia.

It is proposed that **Anders Milton**, a member of the Board of Q-Med since 1997, be re-elected and that he become Chairman of the Board. Anders Milton is, amongst other things, Chairman of dagens.ps AB, ERNA (The European Red Cross/Red Crescent Network on HIV/AIDS and Tuberculosis), Europaskolan Strängnäs, Vironova AB and the Face of Aids Foundation and a member of the Board of Charity Rating, HealthSolutions AB, Transvoice AB and WeMind AB.

It is proposed that **Bengt Ågerup**, a member of the Board of Q-Med since 1987, be re-elected. He is Q-Med's founder, President and CEO. Bengt Ågerup is the Chairman of Stockholm-Uppsala Life Science and OxThera AB and a member of the Board of Envirotainer AB and of the Swedish Foundation for Strategic Research.

It is proposed that **Ulf Mattson** be elected as a new member of the Board. He has an M. Sc. in Business and Economics from Stockholm University, has been a postgraduate student at Stockholm University and has a PMD from Harvard Business School. He has been CEO of Capio AB (publ), Mölnlycke Health Care AB and Domco Tarkett Inc. (publ), based in Montreal. Ulf Mattson is, amongst other things, Chairman of Flextrus AB, Pahlén AB and a member of the Board of Securitas Direct AB NSS Group AB, Din Bostad AB (publ) and Pelly Industrier AB.

It is proposed that **Tomas Nicolin** be elected as a new member of the Board. He has an M.Sc. in Business and Economics from the Stockholm School of Economics and an M.Sc. in Management from MIT Sloan School of Management, Cambridge USA. He has, amongst other things, been the CEO of Alecta, the Third Swedish National Pension Fund and E.Öhman J:or Fondkommission AB, as well as Head of Handelsbanken Markets Asset Management. Tomas Nicolin is, amongst other things, a member of the Board of Nordstjernan AB, Axel and Margaret Ax:son Johnson's Foundation, the Research Institute of Industrial Economics and the Swedish Industry and Commerce Stock Exchange Committee.

It is proposed that **Kristina Persson** be elected as a new member of the Board. She has an M.Sc. in Business and Economics from the Stockholm School of Economics. She is the executive Chairman of the Global Challenge association and has previously been, amongst other things, Deputy Governor at the Swedish Riksbank, the County Governor of Jämtland and a member of the Swedish Parliament. Kristina Persson is, amongst other things, Chairman of the Norden Association and a member of the Board of the Mid Sweden University, the African Wildlife Association, The Natural Step and The Swedish Institute of International Affairs.

Questions should be addressed to:

Robert Wikholm, Chairman of the Election Committee, tel: +46 (0)70 - 714 31 77

Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA™**, for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane®** for filling lines and folds, contouring and creating volume in the face, **Macrolane™** for body contouring, **Durolane™** for the treatment of osteoarthritis of the hip and knee joints, **Deflux®** for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta™** for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.
